Moderna (MRNA) is back in focus after its Q1 2026 earnings, reporting revenue of US$389 million compared with US$108 million a year earlier and a wider net loss of US$1.343 billion driven by litigation costs.

Moderna reported an increase in revenue during the first quarter, citing higher Covid-19 vaccine sales in international markets.

Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports

Moderna (MRNA) reports Q1 earnings May 1 premarket—see consensus EPS (-$3.96), revenue ($236M), and estimate revisions to trade the catalyst.

Moderna's first-quarter sales beat expectations, fueled by government deals outside the US and its first UK shipment under a long-term agreement.

This week, the European Commission authorized Moderna to market the vaccine, mRNA-1083 or mCOMBRIAX, making it the world’s first authorized combination shot for the two respiratory viruses. The decision follows a positive review in February from a key European Medicines Agency’s committee, which paved the way for the approval.

COMBRIAX is the world's first flu plus COVID combination vaccine to receive marketing authorization and Moderna's

Sanofi’s protein-based vaccine Nuvaxovid has conquered Moderna’s next-generation messenger RNA shot mNexspike in a head-to-head trial assessing the tolerability of the two COVID vaccines. In the phase 4 double-blind,

After the Food and Drug Administration initially declined to review Moderna's mRNA flu vaccine candidate, the drugmaker said Wednesday that the FDA reversed its decision and will allow Moderna to move forward. Moderna is seeking approval to administer the ...

CEO Stéphane Bancel expressed confidence in Moderna’s first quarter, touting the revenue numbers as a sign of the company’s return to prosperity.